|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003864,
umls-concept:C0021368,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0026336,
umls-concept:C0026339,
umls-concept:C0029453,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0087111,
umls-concept:C0205276,
umls-concept:C0205373,
umls-concept:C0392760,
umls-concept:C0538161,
umls-concept:C0549193,
umls-concept:C1292733,
umls-concept:C1367028,
umls-concept:C1707455
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-1-27
|
|
pubmed:abstractText |
Rat adjuvant-induced arthritis (AIA) and collagen-induced arthritis (CIA) feature bone loss and systemic increases in TNFalpha, IL-1beta, and receptor activator of NF-kappaB ligand (RANKL). Anti-IL-1 or anti-TNFalpha therapies consistently reduce inflammation in these models, but systemic bone loss often persists. RANKL inhibition consistently prevents bone loss in both models without reducing joint inflammation. Effects of these therapies on systemic markers of bone turnover and inflammation have not been directly compared.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1478-6362
|
|
pubmed:author |
pubmed-author:BolonBradB,
pubmed-author:DuryeaDianeD,
pubmed-author:DwyerDeniseD,
pubmed-author:FeigeUlrichU,
pubmed-author:KostenuikPaulP,
pubmed-author:MiddletonScotS,
pubmed-author:PachecoEfrainE,
pubmed-author:SchettGeorgG,
pubmed-author:StolinaMarinaM,
pubmed-author:VanGwynethG,
pubmed-author:VonderfechtStevenS,
pubmed-author:ZackDebraD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
R187
|
|
pubmed:dateRevised |
2011-1-10
|
|
pubmed:meshHeading |
pubmed-meshheading:20003323-Animals,
pubmed-meshheading:20003323-Antirheumatic Agents,
pubmed-meshheading:20003323-Arthritis, Experimental,
pubmed-meshheading:20003323-Arthritis, Rheumatoid,
pubmed-meshheading:20003323-Bone Density,
pubmed-meshheading:20003323-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:20003323-Immunohistochemistry,
pubmed-meshheading:20003323-Inflammation,
pubmed-meshheading:20003323-Interleukin 1 Receptor Antagonist Protein,
pubmed-meshheading:20003323-Interleukin-1,
pubmed-meshheading:20003323-Osteoprotegerin,
pubmed-meshheading:20003323-RANK Ligand,
pubmed-meshheading:20003323-Rats,
pubmed-meshheading:20003323-Rats, Inbred Lew,
pubmed-meshheading:20003323-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
|
|
pubmed:affiliation |
Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA. mstolina@amgen.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
